CD138 Plasma Cell Enrichment for Genomic Sequencing*

*For Research Use Only - not for use in therapeutic or diagnostic procedures

Advancements in Multiple Myeloma Research through Genomic Sequencing

Multiple myeloma, characterized by its diverse molecular forms, remains a focal point in clinical research. The past decade has seen notable advances, including the development of proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and targeted drugs, greatly transforming outcomes of the disease.1 Today, central to the clinical advancement is the in-depth exploration of Multiple Myeloma’s genetics through Next-Generation Sequencing (NGS) technologies.

NGS technologies do more than just provide data; they are reshaping the landscape of multiple myeloma clinical research. By offering a detailed look into the genetics of myeloma cells, NGS aids researchers in pinpointing essential genetic markers, and techniques such as whole-genome and whole-exome sequencing have revealed critical genetic alterations, opening up fresh avenues for research and development of novel dignostic tools and therapies.2

The emerging potential of NGS in research is evident. Whether it’s tracking how multiple myeloma evolves or differentiating between molecular variants, NGS is proving indispensable in clinical research results.3 Additionally, the versatility of NGS technologies extends to studying the disease across various stages and biological samples, encompassing bone marrow, peripheral blood, and even minimal residual disease.3

1. Raphael Szalat, L MD, and Munshi Nikhil C., MD. “Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches.” American Society of Clinical Oncology. Educational Book. 2016 May 19; 36:e442-e448.

2. Decaux O, Lodé L, Magrangeas F, et al; Intergroupe Francophone du Myélome. Prediction of survival in multiple myeloma based on gene expression profiles: A study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008; 26:4798-4805.

3. Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? Front. Oncol. 2020 Feb 25; 10: Sec. Hematologic Malignancies.

MARS® Platform: Improving Plasma Cell Enrichment

The MARS® platform stands at the forefront as an innovative response to pressing challenges in plasma cell enrichment for genomic sequencing. 

Its cutting-edge in-flow design offers easy isolation workflow, resulting in exceptional purity and recovery of the output sample. What makes it unique, is its ability to isolate target cells, even those at minimal initial concentrations, directly from fresh bone marrow or blood samples.

Embracing simplicity, the MARS® platform employs an intuitive, simplified labelling protocol, followed by an automated and efficient MARS® Immunomagnetic separation. The platform also offers the flexibility to quickly enhance purity without compromising recovery.

Publication highlight

Study on how Multiple Myeloma Evades Targeted Immunotherapies

In latest publication by H. Lee et al2, researchers examined factors leading to antigen escape in multiple myeloma (MM) after treatment with anti-BCMA and anti-GPRC5D CAR T/TCE therapies. The study, which involved genomic sequencing of 30 patients, underscores the need to consider the tumor antigen landscape when designing and selecting targeted immunotherapies for MM.

We’re immensely proud to be mentioned in this groundbreaking research in work recently published in Nature Medicine.

2. Lee, H., Ahn, S., Maity, R. et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29, 2295–2306 (2023).

Myeloma CellQuest Grant

Join us in cutting-edge multiple myeloma clinical research through our exclusive grant opportunity.

Contact us